The Cystic Fibrosis Foundation announced that it has awarded up to $5 million to BiomX Inc. to conduct a Phase 1b/2a clinical trial to test the safety and tolerability of bacteriophage (phage therapy) in Pseudomonas aeruginosa infections in people living with cystic fibrosis.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.358 USD | +5.29% |
|
+6.71% | +27.86% |
05-21 | Transcript : BiomX Inc., Q1 2024 Earnings Call, May 21, 2024 | |
05-20 | BiomX Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+27.86% | 24.99M | |
+20.17% | 126B | |
+24.67% | 118B | |
+25.44% | 27.87B | |
-17.74% | 20.95B | |
-15.17% | 16.92B | |
-15.21% | 16.18B | |
+11.91% | 14.84B | |
-47.10% | 14.79B | |
+54.50% | 14.08B |
- Stock Market
- Equities
- PHGE Stock
- News BiomX Inc.
- CF Foundation Awards Up to $5 Million to BiomX for Potential Phage Therapy